Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX
Lexicon Pharmaceuticals — Q2 2026 Earnings Presentation
22 slides from Lexicon Pharmaceuticals's earnings presentation, Aug 6, 2026
Slide 1: Second Quarter 2026 Earnings
Second Quarter 2026 Earnings August 6, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements • This presentation, including any oral presentation accompanying it, contains “forward-looking statements,” including statements about Lexicon’s strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as pr
Slide 3: Q2 2026 Highlights
Q2 2026 Highlights Mike Exton Ph.D. Director and Chief Executive Officer 3
Slide 4: SONATA-HCM Enrollment Complete
Highlights SONATA-HCM Enrollment Complete Pivotal study of sotagliflozin fully randomized; topline data anticipated Q1 2027 >500 nHCM + Patients randomized, 130+ oHCM Q1 2027 Clinical sites across Topline results substantially exceeding 20 countries Only ongoing Phase 3 anticipated enrollment target
Slide 5: Second Quarter 2026 R&D Highlights
Highlights Second Quarter 2026 R&D Highlights Advancing our pipeline of novel targeted therapies Cardiometabolic AAK1 SOTAGLIFLOZIN LX9851 PILAVAPADIN HCM T1D Heart Failure Obesity Neuropathic Pain Phase 3 Patient exposure — Global Phase 1 study DPNP regulatory path SONATA-HCM identified by FDA Expa
Slide 6: Pipeline Updates
Pipeline Updates Craig Granowitz, M.D. Ph.D. Senior Vice President and Chief Medical Officer 6
Slide 7: Cardiometabolic: Sotagliflozin
Cardiometabolic S O TA G L I F L O Z I N Late-stage development programs in HCM and type 1 diabetes 7
Slide 8: HCM is characterized by adverse cardiac remodeling
Hypertrophic cardiomyopathy (HCM) is characterized by adverse cardiac remodeling associated with myocardial hypertrophy, diastolic dysfunction, and fibrosis Qin, Fuzhong & Pimentel, David & Baka, Tomas & Zhang, Aifeng & Croteau, Dominique & Luptak, Ivan & Colucci, Wilson. (2025). Abstract 4343284: D
Slide 9: nHCM and oHCM: many presentations, one disease
Sotagliflozin in HCM Diastolic Dysfunction is the Underlying Fundamental Issue of Both oHCM and nHCM Many presentations… nHCM one disease oHCM HYPERTROPHIC CARDIOMYOPATHY Characterized by global or The hallmark of Without With localized thickening obstructive disease is a Obstruction Obstruction wit
Slide 10: Mechanistic Benefits of SGLT1 in HCM
Sotagliflozin in HCM Sotagliflozin Predominantly Improves Diastolic Dysfunction By Improving Cardiac Metabolism Mechanistic Benefits SGLT1i expressed predominantly of SGLT1 in HCM in the myocardium1 and increased in ventricular hypertrophy Enhanced calcium handling for myocardial relaxation Improve
Slide 11: SONATA-HCM Phase 3 Study for oHCM and nHCM
Sotagliflozin in HCM SONATA-HCM Phase 3 Study for oHCM and nHCM Enrollment complete; 26-week study with topline data anticipated Q1 2027 SONATA-HCM Primary endpoint: Enrollment Complete Change from baseline in Sotagliflozin 400 mg* >500 patients randomized, KCCQ CSS R 1:1 including both nHCM and Pla
Slide 12: Data from STENO1 Supports ZYNQUISTA NDA Resubmission
Sotagliflozin in T1D Data Received to Date from STENO1 Supports ZYNQUISTA NDA Resubmission Adequate enrollment achieved to provide patient exposure levels discussed with FDA Diabetic ketoacidosis (DKA) rates in the exposed population similar to standard of care and well below InTandem studies STENO1
Slide 13: Phase 1 Trial of LX9851 Ongoing by Novo Nordisk
Partnering Phase 1 Trial of LX9851 Ongoing by Novo Nordisk • First-in-class, non-incretin, oral, small molecule inhibitor of ACSL5 in development for obesity Potential to achieve a and associated metabolic disorders third $10 million • Phase 1 study of LX9851 initiated in March milestone in 2026 • $
Slide 14: Financial Overview
Financial Overview Scott Coiante Chief Financial Officer 14
Slide 15: Q2 2026 Financial Summary
Financials Q2 2026 Financial Summary $ (in millions except per share amounts) As of Q2 2026 Q2 2025 As of June 30, December 31, 2026 2025 Total revenues $0.7 $28.9 Cash, cash equivalents, short- $190.6 $125.2 R&D ($17.4) ($15.7) term investments and restricted cash SG&A ($9.8) ($9.4) Total operating
Slide 16: Q2 2026 Financial Highlights and FY 2026 Guidance
Financials Q2 2026 Financial Highlights and FY 2026 Guidance Q2 2026 Key Full Year 2026 Guidance Financial Highlights Operating Expenses* • Entered into $100 million loan facility with • Total 2026 operating expenses expected to be between Hercules Capital $100 - $110 million • Strengthened balance
Slide 17: Summary
Summary Mike Exton Ph.D. Director and Chief Executive Officer 17
Slide 18: Lexicon's Lead to Succeed strategy in action
Conclusion Lexicon’s Lead to Succeed strategy in action Driving value and growth with opportunities for the greatest patient impact First or only in therapy or class Large Leading markets with clinical and significant need medical expertise 18
Slide 19: Potential to be a first-line therapy in symptomatic HCM
Sotagliflozin in HCM Potential to be a first-line therapy in symptomatic HCM The only HCM agent that works inside and outside the heart to reduce symptoms of HCM, as well as reduce HF and MACE events Sotagliflozin is Novel MOA, with SGLT1 inhibition acting directly on the both a myocardium to modify
Slide 20: Reshaping Lexicon Over the Next 12 Months
Conclusion Reshaping Lexicon Over the Next 12 Months Cardiometabolic AAK1 S O TA G L I F L O Z I N LX9851 P I L AVA PA D I N HCM Heart Failure T1D Obesity Neuropathic Pain and other SONATA on target Viatris ex-U.S. / ex- Data provided to FDA high-value indications for topline data Europe efforts ong
Slide 21: Q&A
Q&A Mike Exton, Ph.D. Craig Granowitz, M.D., Ph.D. Scott Coiante Director and Chief Senior Vice President Senior Vice President Executive Officer and Chief Medical Officer and Chief Financial Officer
Slide 22: Thank You
THANK YOU pharmaceuticals
Lexicon Pharmaceuticals — Q2 2026 Earnings Presentation on 6ix